MYELO001
Phase 2- Indications
- Chemotherapy-induced neutropenia, Chemotherapy-induced thrombocytopenia, Radiation protection
Company intelligence / Profile preview
Myelo Therapeutics
Kastanienallee, Berlin, Germanymyelotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Myelo Therapeutics developed small molecule-based oral therapies targeting the reduction of chemotherapy-induced and radiation-induced myelosuppression, as well as acute radiation syndrome. Their lead candidate ("Myelo001") was being developed for these indications. The company was acquired by Eckert & Ziegler in December 2022 after raising approximately $6 million from various investors including NIH and JSC Valenta Pharmaceuticals. No commercial products are reported; the pipeline appears to have been focused on advancing Myelo001 through clinical stages for high unmet medical needs.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institutes of HealthJSC Valenta PharmaceuticalsIBB BeteiligungsgesellschaftEckert Life Science Accelerator
Beyond the preview
Go deeper on Myelo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myelo Therapeutics.